1 |
Burton, D.R., C.F. Barbas, 3rd, M.A. Persson, S. Koenig, R.M. Chanock, and R.A. Lerner. 1991. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA 88, 10134-10137
|
2 |
Figini, M., L. Obici, D. Mezzanzanica, A. Griffiths, M.I. Colnaghi, G. Winter, and S. Canevari. 1998. Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection. Cancer Res. 58, 991-996
PUBMED
|
3 |
Jespers, L.S., A. Roberts, S.M. Mahler, G. Winter, and H.R. Hoogenboom. 1994. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Bio/Technol. 12, 899-903
DOI
|
4 |
Kashmiri, S.V., L. Shu, E.A. Padlan, D.E. Milenic, J. Schlom, and P.H. Hand. 1995. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Hybridoma 14, 461-473
DOI
ScienceOn
|
5 |
Kim, S.J., M.H. Jang, J.T. Stapleton, S.O. Yoon, K.S. Kim, E.S. Jeon, and H.J. Hong. 2004. Neutralizing human monoclonal antibodies to hepatitis A virus recovered by phage display. Virology 318, 598-607
DOI
ScienceOn
|
6 |
Tamura, M., D.E. Milenic, M. Iwahashi, E. Padlan, J. Schlom, and S.V. Kashmiri. 2000. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only. J. Immunol. 164, 1432-1441
DOI
PUBMED
|
7 |
Iwahashi, M., D.E. Milenic, E.A. Padlan, R. Bei, J. Schlom, and S.V. Kashmiri. 1999. CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity. Mol. Immunol. 36, 1079-1091
DOI
ScienceOn
|
8 |
Yoon, S.O., T.S. Lee, S.J. Kim, M.H. Jang, Y.J. Kang, J.H. Park, K.S. Kim, H.S. Lee, C.J. Ryu, N.R. Gonzales, S.V. Kashmiri, S.M. Lim, C.W. Choi, and H.J. Hong. 2006. Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody. J. Biol. Chem. 281, 6985-6992
DOI
ScienceOn
|
9 |
Thor, A., R. Muraro, F. Gorstein, N. Ohuchi, M. Viglione, C.A. Szpak, W.W. Johnston, and J. Schlom. 1987. Adjunct to the diagnostic distinction between adenocarcinomas of the ovary and the colon utilizing a monoclonal antibody (COL-4) with restricted carcinoembryonic antigen reactivity. Cancer Res. 47, 505-512
PUBMED
|
10 |
Marks, J.D., H.R. Hoogenboom, T.P. Bonnert, J. McCafferty, A.D. Griffiths, and G. Winter. 1991. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222, 581-597
DOI
|
11 |
Thor, A., N. Ohuchi, C.A. Szpak, W.W. Johnston, and J. Schlom. 1986. Distribution of oncofetal antigen tumor-associated glycoprotein- 72 defined by monoclonal antibody B72.3. Cancer Res. 46, 3118-3124
PUBMED
|
12 |
Figini, M., J.D. Marks, G. Winter, and A.D. Griffiths. 1994. In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation. J. Mol. Biol. 239, 68-78
DOI
ScienceOn
|
13 |
Divgi, C.R., A.M. Scott, S. Gulec, E.K. Broussard, N. Levy, C. Young, P. Capitelli, F. Daghighian, J.M. Williams, and R.D. Finn. 1995b. Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma. Clin. Cancer Res. 1, 1503-1510
PUBMED
|
14 |
Watzka, H., K. Pfizenmaier, and D. Moosmayer. 1998. Guided selection of antibody fragments specific for human interferon gamma receptor 1 from a human VH- and VL-gene repertoire. Immunotechnology 3, 279-291
DOI
ScienceOn
|
15 |
Gonzales, N.R., E.A. Padlan, R. De Pascalis, P. Schuck, J. Schlom, and S.V. Kashmiri. 2003. Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues. Mol. Immunol. 40, 337-349
DOI
ScienceOn
|
16 |
De Pascalis, R., N.R. Gonzales, E.A. Padlan, P. Schuck, S.K. Batra, J. Schlom, and S.V. Kashmiri. 2003. In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants. Clin. Cancer Res. 9, 5521-5531
PUBMED
|
17 |
Divgi, C.R., A.M. Scott, L. Dantis, P. Capitelli, K. Siler, S. Hilton, R.D. Finn, N. Kemeny, D. Kelsen, L. Kostakoglu, J. Schlom, and S.M. Larson. 1995a. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J. Nucl. Med. 36, 586-592
|
18 |
Pavlinkova, G., D. Colcher, B.J. Booth, A. Goel, and S.K. Batra. 2000. Pharmacokinetics and biodistribution of a light-chainshuffled CC49 single-chain Fv antibody construct. Cancer Immunol. Immunother. 49, 267-275
DOI
|
19 |
Mulligan, T., J.A. Carrasquillo, Y. Chung, D.E. Milenic, J. Schlom, I. Feuerstein, C. Paik, P. Perentesis, J. Reynolds, and G. Curt. 1995. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin. Cancer Res. 1, 1447-1454
PUBMED
|
20 |
Beiboer, S.H., A. Reurs, R.C. Roovers, J.W. Arends, N.R. Whitelegg, A.R. Rees, and H.R. Hoogenboom. 2000. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent. J. Mol. Biol. 296, 833-849
DOI
ScienceOn
|
21 |
Divgi, C.R., A.M. Scott, K. McDermott, P.S. Fallone, S. Hilton, K. Siler, N. Carmichael, F. Daghighian, R.D. Finn, A.M. Cohen, J. Schlom, and S.M. Larson. 1994. Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen. Nucl. Med. Biol. 21, 9-15
DOI
ScienceOn
|
22 |
Persson, M.A., R.H. Caothien, and D.R. Burton. 1991. Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning. Proc. Natl. Acad. Sci. USA 88, 2432-2436
|